What do I talk about when I talk about measuring CNS orexin-A? Considerations of orexin-A measurements in clinical and preclinical setting

by Jyrki P. Kukkonen
Published 2021-09-01

OX1 and OX2 orexin/hypocretin receptor pharmacogenetics

by Miles Douglas Thompson, Henri eXhaard, Takeshi eSakurai, Innocenzo eRainero, Jyrki P. Kukkonen, Jyrki P. Kukkonen
Published 2014-05-01

Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics

by Miles D. Thompson, Takeshi Sakurai, Innocenzo Rainero, Mary C. Maj, Jyrki P. Kukkonen
Published 2017-10-01

Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity.

by Ainoleena Turku, Maiju K Rinne, Gustav Boije Af Gennäs, Henri Xhaard, Dan Lindholm, Jyrki P Kukkonen
Published 2017-01-01

Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells

by Jinar Rostami, Maria Jäntti, Hengjing Cui, Maiju K. Rinne, Jyrki P. Kukkonen, Anna Falk, Anna Erlandsson, Timo Myöhänen
Published 2020-11-01

Corrigendum to “Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells” [Biomed. Pharmacother. 131 (2020) 110788]

by Jinar Rostami, Maria Jäntti, Hengjing Cui, Maiju K. Rinne, Jyrki P. Kukkonen, Anna Falk, Anna Erlandsson, Timo Myöhänen
Published 2021-01-01

No evidence of autoimmunity to human OX1 or OX2 orexin receptors in Pandemrix-vaccinated narcoleptic children

by Krister Melén, Pinja Jalkanen, Jyrki P. Kukkonen, Markku Partinen, Hanna Nohynek, Arja Vuorela, Outi Vaarala, Tobias L. Freitag, Seppo Meri, Ilkka Julkunen
Published 2020-01-01